Trial Profile
A Phase I, Open-label, Dose-escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of Cafusertib Hydrochloride in Patients With Advanced Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 28 Feb 2017
Price :
$35
*
At a glance
- Drugs Cafusertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Jiangsu Hansoh Pharmaceutical
- 15 Dec 2014 New trial record